sulthiame has been researched along with Epilepsy in 42 studies
sulthiame: was heading 1964-94 (see under THIAZINES 1964-90); use THIAZINES to search SULTHIAME 1966-94
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To show non-inferiority of levetiracetam to sulthiame with respect to efficacy, tolerability and safety in benign epilepsy with centrotemporal spikes in a prospective, double-blinded randomized controlled trial." | 9.17 | Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). ( Bast, T; Bonfert, M; Borggraefe, I; Heinen, F; Maßmann, K; May, TW; Neubauer, BA; Noachtar, S; Schotten, KJ; Tuxhorn, I, 2013) |
| " Small sample sizes, poor methodological quality, and lack of data on important outcome measures precluded any meaningful conclusions regarding the efficacy and tolerability of sulthiame as monotherapy in epilepsy." | 9.12 | Sulthiame monotherapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Panebianco, M, 2021) |
| "This prospective uncontrolled open study explored the efficacy and long-term tolerability of sulthiame (STM) in 52 patients with refractory epilepsy and learning disability." | 9.10 | Sulthiame in adults with refractory epilepsy and learning disability: an open trial. ( Koepp, MJ; Patsalos, PN; Sander, JW, 2002) |
| "To assess the efficacy and tolerability of sulthiame as add-on therapy for people with epilepsy of any aetiology compared with placebo or another antiepileptic drug." | 9.01 | Sulthiame add-on therapy for epilepsy. ( Bresnahan, R; Marson, AG; Martin-McGill, KJ; Milburn-McNulty, P; Powell, G; Sills, GJ, 2019) |
| "Randomised controlled add-on trials of sulthiame in people of any age with epilepsy of any aetiology." | 8.91 | Sulthiame add-on therapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Powell, G; Sills, GJ, 2015) |
| "Small sample size, poor methodological quality and lack of data on important outcome measures prevent any meaningful conclusions regarding the efficacy and safety of sulthiame as monotherapy in epilepsy." | 8.90 | Sulthiame monotherapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Powell, G; Sills, GJ, 2014) |
| "Randomised placebo-controlled add-on trials of sulthiame in people of any age with epilepsy of any aetiology." | 8.89 | Sulthiame add-on therapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Powell, G; Sills, GJ, 2013) |
| "The charts of 125 consecutive epilepsy patients treated with sulthiame as monotherapy or add-on therapy were reviewed." | 7.72 | Sulthiame in childhood epilepsy. ( Barash, I; Ben-Zeev, B; Brand, N; Lerman, P; Lerman-Sagie, T; Watemberg, N, 2004) |
| "Sulthiame is effectively used in the treatment of benign and symptomatic focal epilepsy in children." | 7.69 | Sulthiame-associated mild compensated metabolic acidosis. ( Darius, J; Fritzsch, C; Gedschold, J; Meyer, FP; Tröger, U, 1996) |
| "9%) seizure frequency was reduced by more than 50% (mean FBM dosage 3211 mg), and 13 patients (31." | 5.34 | [Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame]. ( Bauer, J; Chahem, J, 2007) |
| "To show non-inferiority of levetiracetam to sulthiame with respect to efficacy, tolerability and safety in benign epilepsy with centrotemporal spikes in a prospective, double-blinded randomized controlled trial." | 5.17 | Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). ( Bast, T; Bonfert, M; Borggraefe, I; Heinen, F; Maßmann, K; May, TW; Neubauer, BA; Noachtar, S; Schotten, KJ; Tuxhorn, I, 2013) |
| " Small sample sizes, poor methodological quality, and lack of data on important outcome measures precluded any meaningful conclusions regarding the efficacy and tolerability of sulthiame as monotherapy in epilepsy." | 5.12 | Sulthiame monotherapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Panebianco, M, 2021) |
| "This prospective uncontrolled open study explored the efficacy and long-term tolerability of sulthiame (STM) in 52 patients with refractory epilepsy and learning disability." | 5.10 | Sulthiame in adults with refractory epilepsy and learning disability: an open trial. ( Koepp, MJ; Patsalos, PN; Sander, JW, 2002) |
| "To assess the efficacy and tolerability of sulthiame as add-on therapy for people with epilepsy of any aetiology compared with placebo or another antiepileptic drug." | 5.01 | Sulthiame add-on therapy for epilepsy. ( Bresnahan, R; Marson, AG; Martin-McGill, KJ; Milburn-McNulty, P; Powell, G; Sills, GJ, 2019) |
| "Randomised controlled add-on trials of sulthiame in people of any age with epilepsy of any aetiology." | 4.91 | Sulthiame add-on therapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Powell, G; Sills, GJ, 2015) |
| "Small sample size, poor methodological quality and lack of data on important outcome measures prevent any meaningful conclusions regarding the efficacy and safety of sulthiame as monotherapy in epilepsy." | 4.90 | Sulthiame monotherapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Powell, G; Sills, GJ, 2014) |
| "Randomised placebo-controlled add-on trials of sulthiame in people of any age with epilepsy of any aetiology." | 4.89 | Sulthiame add-on therapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Powell, G; Sills, GJ, 2013) |
| "The introduction of these new antiepileptic drugs, from felbamate to levetiracetam, raised hope of control of epilepsy with fewer adverse effects and improved quality of life." | 4.81 | New antiepileptic drug therapies. ( Bergin, AM; Connolly, M, 2002) |
| "Sulthiame is an old antiepileptic drug primarily used in a few European countries for the treatment of benign epilepsy of childhood with central temporal spikes." | 3.77 | Sulthiame in refractory paediatric epilepsies: an experience of an 'old' antiepileptic drug in a tertiary paediatric neurology unit. ( Appleton, R; Eaton, V; Hawcutt, D; Kneen, R; Kumar, R; Stockton, F; Swiderska, N, 2011) |
| "The charts of 125 consecutive epilepsy patients treated with sulthiame as monotherapy or add-on therapy were reviewed." | 3.72 | Sulthiame in childhood epilepsy. ( Barash, I; Ben-Zeev, B; Brand, N; Lerman, P; Lerman-Sagie, T; Watemberg, N, 2004) |
| "Sulthiame is a carbonic anhydrase (CA) inhibitor with an anticonvulsant effect in the treatment of benign and symptomatic focal epilepsy in children." | 3.71 | Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons. ( Bingmann, D; Bonnet, U; Hufnagel, A; Leniger, T; Widman, G; Wiemann, M, 2002) |
| "Sulthiame is effectively used in the treatment of benign and symptomatic focal epilepsy in children." | 3.69 | Sulthiame-associated mild compensated metabolic acidosis. ( Darius, J; Fritzsch, C; Gedschold, J; Meyer, FP; Tröger, U, 1996) |
| "9%) seizure frequency was reduced by more than 50% (mean FBM dosage 3211 mg), and 13 patients (31." | 1.34 | [Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame]. ( Bauer, J; Chahem, J, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (52.38) | 18.7374 |
| 1990's | 1 (2.38) | 18.2507 |
| 2000's | 7 (16.67) | 29.6817 |
| 2010's | 9 (21.43) | 24.3611 |
| 2020's | 3 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Milburn-McNulty, P | 5 |
| Panebianco, M | 1 |
| Marson, AG | 5 |
| Bresnahan, R | 1 |
| Martin-McGill, KJ | 1 |
| Powell, G | 4 |
| Sills, GJ | 4 |
| Madej, K | 1 |
| Paprotny, Ł | 1 |
| Wianowska, D | 1 |
| Kasprzyk, J | 1 |
| Herman, M | 1 |
| Piekoszewski, W | 1 |
| Liguori, S | 1 |
| Borggraefe, I | 1 |
| Bonfert, M | 1 |
| Bast, T | 1 |
| Neubauer, BA | 1 |
| Schotten, KJ | 1 |
| Maßmann, K | 1 |
| Noachtar, S | 1 |
| Tuxhorn, I | 1 |
| May, TW | 1 |
| Heinen, F | 1 |
| Yamamoto, Y | 1 |
| Takahashi, Y | 1 |
| Imai, K | 1 |
| Mogami, Y | 1 |
| Matsuda, K | 1 |
| Nakai, M | 1 |
| Kagawa, Y | 1 |
| Inoue, Y | 1 |
| Tan, HJ | 1 |
| Singh, J | 1 |
| Gupta, R | 1 |
| de Goede, C | 1 |
| Rauchenzauner, M | 1 |
| Griesmacher, A | 1 |
| Tatarczyk, T | 1 |
| Haberlandt, E | 1 |
| Strasak, A | 1 |
| Zimmerhackl, LB | 1 |
| Falkensammer, G | 1 |
| Luef, G | 1 |
| Högler, W | 1 |
| Swiderska, N | 1 |
| Hawcutt, D | 1 |
| Eaton, V | 1 |
| Stockton, F | 1 |
| Kumar, R | 1 |
| Kneen, R | 1 |
| Appleton, R | 1 |
| Koepp, MJ | 1 |
| Patsalos, PN | 1 |
| Sander, JW | 1 |
| Bergin, AM | 1 |
| Connolly, M | 1 |
| ENGELMEIER, MP | 1 |
| FLUEGEL, F | 1 |
| BENTE, D | 1 |
| ITIL, T | 1 |
| RAFFAUF, HJ | 1 |
| HAJNSEK, F | 1 |
| BOHACEK, N | 1 |
| OVERVAD, E | 1 |
| HARAN, T | 2 |
| INGRAM, TT | 1 |
| RATCLIFFE, SG | 1 |
| TAEN, S | 1 |
| GOTO, Y | 1 |
| ARAI, S | 1 |
| TOKUDA, Y | 1 |
| ODAWARA, K | 1 |
| HIRAI, M | 1 |
| BRAY, CA | 1 |
| BOWER, BD | 1 |
| SUTHERLAND, JM | 1 |
| BOWMAN, DA | 1 |
| GARLAND, H | 1 |
| SUMNER, D | 1 |
| GRIFFITHS, AW | 1 |
| SYLVESTER, PE | 1 |
| DOOSE, H | 1 |
| KLUGE, D | 1 |
| EHMSEN, U | 1 |
| GORDON, N | 2 |
| FENTON, G | 1 |
| SERAFETINIDES, EA | 1 |
| POND, DA | 1 |
| MELIN, KA | 1 |
| GAYLOR, JB | 1 |
| SMYTH, VO | 1 |
| SONNENREICH, C | 1 |
| RABE, F | 1 |
| PENIN, H | 1 |
| MATTHES, A | 1 |
| Go, T | 1 |
| Ben-Zeev, B | 1 |
| Watemberg, N | 1 |
| Lerman, P | 1 |
| Barash, I | 1 |
| Brand, N | 1 |
| Lerman-Sagie, T | 1 |
| Huppke, P | 1 |
| Kallenberg, K | 1 |
| Gärtner, J | 1 |
| Chahem, J | 1 |
| Bauer, J | 1 |
| Tröger, U | 1 |
| Fritzsch, C | 1 |
| Darius, J | 1 |
| Gedschold, J | 1 |
| Meyer, FP | 1 |
| Leniger, T | 1 |
| Wiemann, M | 1 |
| Bingmann, D | 1 |
| Widman, G | 1 |
| Hufnagel, A | 1 |
| Bonnet, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| HEAD-TO-HEAD Evaluation of the Antiepileptic Drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German Multi-Centre, Doubleblind Controlled Trial in Children With Benign Epilepsy With Centro-Temporal Spikes[NCT00471744] | Phase 3 | 44 participants (Actual) | Interventional | 2006-06-30 | Terminated (stopped due to low patient number after 2 years recruiting) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for sulthiame and Epilepsy
| Article | Year |
|---|---|
Sulthiame monotherapy for epilepsy.
Topics: Anticonvulsants; Epilepsy; Humans; Quality of Life; Randomized Controlled Trials as Topic; Thiazines | 2021 |
Sulthiame add-on therapy for epilepsy.
Topics: Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Humans; Infant; Male; Quality of Life; | 2019 |
Sulthiame add-on therapy for epilepsy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Infant; Male; Randomized Controlled Trials as Topic; Spas | 2013 |
Sulthiame monotherapy for epilepsy.
Topics: Adult; Anticonvulsants; Child; Child, Preschool; Early Termination of Clinical Trials; Epilepsy; Epi | 2014 |
Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes.
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Clobazam; Epilepsy; Fructose; Humans; Induct | 2014 |
Sulthiame add-on therapy for epilepsy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Infant; Male; Pyridoxine; Randomized Controlled Trials as | 2015 |
New antiepileptic drug therapies.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Ep | 2002 |
ADVANCES IN NEUROLOGY.
Topics: Drug Therapy; Epilepsy; Headache; Methysergide; Migraine Disorders; Multiple Sclerosis; Nervous Syst | 1964 |
2 trials available for sulthiame and Epilepsy
| Article | Year |
|---|---|
Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study).
Topics: Anticonvulsants; Child; Double-Blind Method; Drug Therapy, Combination; Epilepsy; Female; Humans; Le | 2013 |
Sulthiame in adults with refractory epilepsy and learning disability: an open trial.
Topics: Adult; Epilepsy; Female; Follow-Up Studies; Humans; Learning Disabilities; Male; Middle Aged; Neutro | 2002 |
32 other studies available for sulthiame and Epilepsy
| Article | Year |
|---|---|
A fully validated HPLC-UV method for determination of sulthiame in human serum/plasma samples.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Chromatography, High Pressure Liquid; D | 2021 |
Is sulthiame effective and tolerated as add-on therapy for infants with epilepsy? A Cochrane Review summary with commentary.
Topics: Epilepsy; Humans; Infant; Thiazines | 2021 |
Interaction between sulthiame and clobazam: sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19.
Topics: Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Cytochrome P-450 CYP2C19 | 2014 |
Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children.
Topics: Anthropometry; Anticonvulsants; Body Composition; Body Height; Body Mass Index; Body Weight; Carbama | 2010 |
Sulthiame in refractory paediatric epilepsies: an experience of an 'old' antiepileptic drug in a tertiary paediatric neurology unit.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Hospital Units; Humans; Male | 2011 |
[On the clinical evaluation of anti-epileptic medications with special reference to Ospolot].
Topics: Anticonvulsants; Epilepsy; Heterocyclic Compounds; Thiazines | 1960 |
[On the role of the butanesultam derivative Ospolot in the treatment of cerebral epilepsy].
Topics: Anticonvulsants; Epilepsy; Heterocyclic Compounds; Thiazines | 1960 |
[The treatment of cerebral epilepsy with Ospolot].
Topics: Anticonvulsants; Epilepsy; Heterocyclic Compounds; Thiazines | 1960 |
[Our experience in the therapy of some refractory forms of epilepsy with Ospolot].
Topics: Cardiovascular Agents; Epilepsy; Heterocyclic Compounds; Muscle Relaxants, Central; Thiazines | 1961 |
[Ospolot, a new preparation for the treatment of epilepsy].
Topics: Epilepsy; Heterocyclic Compounds; Thiazines | 1962 |
OSPOLOT: a preliminary communication.
Topics: Anticonvulsants; Communication; Epilepsy; Heterocyclic Compounds; Thiazines | 1962 |
Clinical trial of Ospolot in epilepsy.
Topics: Anticonvulsants; Epilepsy; Humans; Thiazines | 1963 |
[Therapeutic effect of N-(4-sulfamoylphenyl)-1,4-butanesultam (Ospolot) on epilepsy].
Topics: Anticonvulsants; Epilepsy; Thiazines | 1962 |
OSPOLOT IN EPILEPSY.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Humans; Infant; Thiazines; Toxicology | 1963 |
SULTHIAMINE ("OSPOLOT") IN THE TREATMENT OF TEMPORAL LOBE EPILEPSY.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Epilepsy, Temporal Lobe; Humans; Infant; Temporal Lobe | 1963 |
SULTHIAME IN TREATMENT OF EPILEPSY.
Topics: Adolescent; Anticonvulsants; Epilepsy; Pharmacology; Statistics as Topic; Sulfanilamide; Sulfanilami | 1964 |
SULTHIAME TREATMENT OF EPILEPSY.
Topics: Anticonvulsants; Dysmenorrhea; Epilepsy; Female; Humans; Thiazines; Toxicology | 1964 |
OSPOLOT--A CLINICAL TRIAL OF A NEW ANTICONVULSANT.
Topics: Anticonvulsants; Electroencephalography; Epilepsy; Humans; Intellectual Disability; Pathology; Pharm | 1964 |
[EXPERIENCES WITH OSPOLOT IN THE TREATMENT OF INFANTILE EPILEPSY].
Topics: Anticonvulsants; Child; Epilepsy; Epilepsy, Absence; Epilepsy, Temporal Lobe; Epilepsy, Tonic-Clonic | 1964 |
SULTHIAME (OSPOLOT) IN THE TREATMENT OF EPILEPSY.
Topics: Anticonvulsants; Child; Child Behavior Disorders; Epilepsy; Epilepsy, Temporal Lobe; Epilepsy, Tonic | 1964 |
THE USE OF OSPOLOT IN THE TREATMENT OF EPILEPSY.
Topics: Anticonvulsants; Biomedical Research; Child; Drug Therapy; Epilepsy; Epilepsy, Absence; Epilepsy, Te | 1964 |
THE EFFECT OF SULTHIAME, A NEW ANTICONVULSANT DRUG IN THE TREATMENT OF TEMPORAL LOBE EPILEPSY.
Topics: Adolescent; Anticonvulsants; Drug Therapy; Dyspnea; Epilepsy; Epilepsy, Temporal Lobe; Humans; Paran | 1964 |
[OSPOLOT, A NEW ANTICONVULSANT. REPORT SUMMING UP 2 YEARS OF CLINICAL TRIALS].
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Heterocyclic Compounds; Humans; Thiazines | 1964 |
THE USE OF OSPOLOT IN TEMPORAL LOBE EPILEPSY. A PRELIMINARY COMMUNICATION.
Topics: Anticonvulsants; Drug Therapy; Epilepsy; Epilepsy, Temporal Lobe; Heterocyclic Compounds; Humans; Te | 1964 |
[OSPOLOT IN EPILEPSY TREATMENT].
Topics: Anticonvulsants; Drug Therapy; Epilepsy; Thiazines | 1965 |
[Experiences with Ospolot in the treatment of epilepsy].
Topics: Epilepsy; Heterocyclic Compounds; Thiazines | 1962 |
Effect of antiepileptic drug monotherapy on crystalluria in children and young adults.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Female; Humans; Isoxazoles; Male; Retrospective Studie | 2003 |
Sulthiame in childhood epilepsy.
Topics: Adolescent; Australia; Child; Child, Preschool; Dose-Response Relationship, Drug; Epilepsy; Female; | 2004 |
Perisylvian polymicrogyria in Landau-Kleffner syndrome.
Topics: Cerebral Arteries; Cerebral Cortex; Child; Electroencephalography; Epilepsy; Humans; Landau-Kleffner | 2005 |
[Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame].
Topics: Adult; Anticonvulsants; Epilepsy; Felbamate; Humans; Nipecotic Acids; Phenylcarbamates; Propylene Gl | 2007 |
Sulthiame-associated mild compensated metabolic acidosis.
Topics: Acidosis; Anticonvulsants; Blood Gas Analysis; Child, Preschool; Epilepsy; Humans; Male; Thiazines | 1996 |
Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons.
Topics: Acetazolamide; Animals; Anticonvulsants; Benzolamide; Carbonic Anhydrase Inhibitors; Epilepsy; Guine | 2002 |